Atria Investments Inc Has $5.54 Million Stock Holdings in Sanofi $SNY

Atria Investments Inc trimmed its position in Sanofi (NASDAQ:SNY) by 12.2% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 117,300 shares of the company’s stock after selling 16,347 shares during the period. Atria Investments Inc’s holdings in Sanofi were worth $5,537,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Financial Consulate Inc. bought a new position in Sanofi in the third quarter valued at about $26,000. First Horizon Corp bought a new position in shares of Sanofi in the 3rd quarter valued at about $33,000. Salomon & Ludwin LLC boosted its stake in shares of Sanofi by 1,046.3% in the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after purchasing an additional 701 shares during the last quarter. Nisa Investment Advisors LLC grew its position in shares of Sanofi by 233.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $48,000 after buying an additional 700 shares during the period. Finally, Traub Capital Management LLC bought a new stake in shares of Sanofi during the second quarter worth approximately $51,000. Institutional investors own 14.03% of the company’s stock.

Sanofi News Summary

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on SNY shares. HSBC reissued a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Citigroup initiated coverage on shares of Sanofi in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, Wall Street Zen upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Five research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $62.67.

Sanofi Trading Down 2.2%

Shares of NASDAQ:SNY opened at $46.01 on Friday. The company’s 50-day moving average price is $47.73 and its two-hundred day moving average price is $48.59. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.29. The stock has a market capitalization of $112.22 billion, a PE ratio of 12.78, a price-to-earnings-growth ratio of 1.20 and a beta of 0.45.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.